<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39146859</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>02</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>22</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>17</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial.</ArticleTitle><Pagination><StartPage>126216</StartPage><MedlinePgn>126216</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126216</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)00898-3</ELocationID><Abstract><AbstractText>In 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended introduction of at least one inactivated poliovirus vaccine (IPV) dose in essential immunization programs. We evaluated systemic humoral and intestinal mucosal immunity of a sequential IPV-bivalent oral poliovirus vaccine (bOPV) schedule compared with a co-administration IPV + bOPV schedule in an open-label, randomized, controlled, non-inferiority, inequality trial in Dhaka, Bangladesh. Healthy infants aged 6 weeks were randomized to either: (A) IPV and bOPV at 6 and bOPV at 10 and 14 weeks (IPV + bOPV-bOPV-bOPV); or (B) IPV at 6 and bOPV at 10 and 14 weeks (IPV-bOPV-bOPV). Of 456 participants enrolled and randomly assigned during May-August 2015, 428 (94%) were included in the modified intention-to-treat analysis (arm A: 211, arm B: 217). Humoral immune responses did not differ at 18 weeks between study arms: type 1 (98% versus 96%; p = 0.42), type 2 (37% versus 39%; p = 0.77), and type 3 (97% versus 93%; p = 0.07). Virus shedding one week after the bOPV challenge dose in arm B was non-inferior to arm A (type 1 difference = -3% [90% confidence interval: -6 - 0.4%]; type 3 difference: -3% [-6 to -0.2%]). Twenty-six adverse events including seven serious adverse events were reported among 25 participants including one death; none were attributed to study vaccines. An IPV-bOPV-bOPV sequential schedule induced comparable systemic humoral immunity to all poliovirus types and types 1 and 3 intestinal mucosal immunity as an IPV + bOPV-bOPV-bOPV co-administration schedule.</AbstractText><CopyrightInformation>Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Snider</LastName><ForeName>Cynthia J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaman</LastName><ForeName>Khalequ</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estivariz</LastName><ForeName>Concepcion F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA. Electronic address: cge3@cdc.gov.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aziz</LastName><ForeName>Asma Binte</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yunus</LastName><ForeName>Mohammad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haque</LastName><ForeName>Warda</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>icddr,b, 68 Shahid Tajuddin Ahmed Sarani, Dhaka 1212, Bangladesh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hendley</LastName><ForeName>William S</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weldon</LastName><ForeName>William C</ForeName><Initials>WC</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberste</LastName><ForeName>M Steven</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Abhijeet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>U.S. Centers for Disease Control and Prevention, 1600 Clifton Road Northeast, Atlanta, GA 30329, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="Y">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001459" MajorTopicYN="N" Type="Geographic">Bangladesh</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="Y">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018928" MajorTopicYN="Y">Immunity, Mucosal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056724" MajorTopicYN="Y">Immunity, Humoral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bangladesh</Keyword><Keyword MajorTopicYN="N">Bivalent oral poliovirus vaccine</Keyword><Keyword MajorTopicYN="N">Immunogenicity</Keyword><Keyword MajorTopicYN="N">Inactivated poliovirus vaccine</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Khalequ Zaman, Asma Binte Aziz, Mohammad Yunus, Warda Haque b reports financial support was provided by Centers for Disease Control and Prevention. Cynthia J Snider’s spouse previously owned stock in Sanofi Pasteur</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>4</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>3</Day><Hour>1</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>16</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>15</Day><Hour>18</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39146859</ArticleId><ArticleId IdType="mid">NIHMS2023316</ArticleId><ArticleId IdType="pmc">PMC11460026</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126216</ArticleId><ArticleId IdType="pii">S0264-410X(24)00898-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sutter RW, Kew OM, Cochi SL, Aylward RB. Poliovirus vaccine - live. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. 6th ed. Elsevier; 2013. p. 598–645.</Citation></Reference><Reference><Citation>Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis 2014;210(Suppl. 1):S380–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10424844</ArticleId><ArticleId IdType="pubmed">25316859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hird TR, Grassly NC. Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 2012;8:e1002599. 10.1371/journal.ppat.1002599.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1002599</ArticleId><ArticleId IdType="pmc">PMC3330118</ArticleId><ArticleId IdType="pubmed">22532797</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio vaccines and polio immunization in the preeradication era: WHO position paper. Wkly Epidemiol Rec 2010;85:213–28.</Citation><ArticleIdList><ArticleId IdType="pubmed">20545051</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio vaccines: WHO position paper – March, 2016. Wkly Epidemiol Rec
2016;91:145–68. https://apps.who.int/iris/handle/10665/357168.
</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2012 — conclusions and recommendations. Wkly Epidemiol Rec
2013;88:1–16. https://apps.who.int/iris/bitstream/handle/10665/242011/WER8801_1-6.PDF?sequence=1&amp;isAllowed=y.
</Citation><ArticleIdList><ArticleId IdType="pubmed">23311010</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2013 – conclusions and recommendations. Wkly Epidemiol Rec
2014;89:1–19. https://www.who.int/publications/i/item/WER8901.
</Citation><ArticleIdList><ArticleId IdType="pubmed">24466571</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization. Practical guide: Inactivated poliovirus vaccine (IPV) introduction. Washington, DC. https://www.paho.org/hq/dmdocuments/2014/Polio-ipv-2014-eng.pdf; 2014.</Citation></Reference><Reference><Citation>Anand A, Pallansch MA, Estivariz CF, Gary H, Wassilak SG. Estimating the likely coverage of inactivated poliovirus vaccine in routine immunization: evidence from demographic and health surveys. J Infect Dis 2014;210(Suppl. 1):S465–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10287983</ArticleId><ArticleId IdType="pubmed">25316869</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO/UNICEF Immunization Coverage: Immunization data dashboard, global. Diphtheria tetanus toxoid and pertussis (DTP) vaccination coverage. Available at, https://immunizationdata.who.int/index.html. [Accessed 22 August 2022].</Citation></Reference><Reference><Citation>Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis 1990;162:1291–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">2172403</ArticleId></ArticleIdList></Reference><Reference><Citation>Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA. Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore area polio vaccine study group. J Infect Dis 1997;175(Suppl. 1):S228–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">9203721</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsay ME, Begg NT, Gandhi J, Brown D. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994;13:1117–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">7892081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y, Xu K, Han W, Chu K, Jiang D, Wang J, et al. Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China. Open Forum Infect Dis 2019;6:ofz380. 10.1093/ofid/ofz380.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofz380</ArticleId><ArticleId IdType="pmc">PMC6786509</ArticleId><ArticleId IdType="pubmed">31660344</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Ryan M, Bandyopadhyay AS, Villena R, Espinoza M, Novoa J, Weldon WC, et al. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study. Lancet Infect Dis 2015;15:1273–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">26318714</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu J, Yang Y, Huang L, Wang L, Jiang Z, Gong J, et al. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: a randomized controlled non-inferiority clinical trial. Hum Vaccin Immunother 2017;13:1–10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5489289</ArticleId><ArticleId IdType="pubmed">28362135</ArticleId></ArticleIdList></Reference><Reference><Citation>Anand A, Zaman K, Estivariz CF, Yunus M, Gary HE, Weldon WC, et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: a randomized controlled trial. Vaccine 2015;33:6816–22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10423714</ArticleId><ArticleId IdType="pubmed">26476367</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Multicentre Growth Reference Study Group. WHO child growth standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization; 2006. Available at, https://www.who.int/tools/child-growth-standards/who-multicentre-growth-reference-study. [Accessed 15 September 2021].</Citation></Reference><Reference><Citation>Weldon WC, Oberste MS, Pallansch MA. Standardized methods for detection of poliovirus antibodies. Methods Mol Biol 2016;1387:145–76. 10.1007/978-1-4939-3292-4_8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-3292-4_8</ArticleId><ArticleId IdType="pubmed">26983734</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio laboratory manual. In: Immunization V, and Biologicals, editor. 4th ed.
Geneva; 2004. Available at, https://polioeradication.org/wp-content/uploads/2017/05/Polio_Lab_Manual04.pdf. [Accessed 15 September 2021].</Citation></Reference><Reference><Citation>Resik S, Tejeda A, Sutter RW, Diaz M, Sarmiento L, Alemani N, et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med 2013;368:416–24.</Citation><ArticleIdList><ArticleId IdType="pubmed">23363495</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Polio vaccines: WHO position paper – June 2022. Wkly Epidemiol Rec
2022;97:277–300. https://apps.who.int/iris/handle/10665/357168.</Citation></Reference><Reference><Citation>UK Health Security Agency. Poliovirus detected in sewage from North and East London. Investigation underway to protect public, who are urged to ensure polio vaccines are up to date, especially parents of young children who may have missed an immunisation opportunity. UK Health Security Agency press office; 2022. Available at, https://www.gov.uk/government/news/poliovirus-detected-in-sewage-from-north-and-east-london. [Accessed 9 February 2023].</Citation></Reference><Reference><Citation>Link-Gelles R, Lutterloh E, Schnabel Ruppert P, Backenson PB, St George K, Rosenberg ES, et al.
Public health response to a case of paralytic poliomyelitis in an unvaccinated person and detection of poliovirus in wastewater - New York, June-August 2022. MMWR Morb Mortal Wkly Rep
2022;71:1065–8. https://www.ncbi.nlm.nih.gov/pubmed/35980868.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9400530</ArticleId><ArticleId IdType="pubmed">35980868</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Circulating vaccine-derived poliovirus type 2 (cVDPV2) – Ukraine. Available at, https://www.who.int/emergencies/disease-outbreak-news/item/circulating-vaccine-derived-poliovirus-type-2-(cvdpv2)-ukraine. [Accessed 22 October 2021].</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>